Aktuellt
SENASTE
Redeye comments on Lipigon’s first-quarter report. After the end of Q1, all patients in the phase I study of Lipisense have been treated without any serious adverse events. The data is being analysed at the same time as a phase IIa study is being planned towards the end of the year.
LÄS MER
